What does this research mean for the field?

Q: What does this research mean for the field?

Adding the GLP-1RA Dulaglutide to SGLT2 inhibitor therapy significantly reduces HbA1c, body mass index, and body weight in obese type 2 diabetic patients at high cardiovascular risk in a real-world setting, regardless of age, diabetes duration, or baseline CVD risk. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

November 28, 2024Pharmacological Research14 citationsOpen Access

Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE−2 study

CBCesare BerraMultiMedica RMRoberto ManfriniAOL (United States)FBFrancesco BifariRegenerative Medicine Institute

Key Points

Key points are not available for this paper at this time.

Abstract

; p<0.0001). Efficacy of Dulaglutide was not affected by different CVD risk categories, age and T2DM duration. This real world study provides evidence for significant reductions in HbA1c level, body mass index and body weight in obese type 2 diabetic patients who received add-on treatment with the weekly GLP-1RA, Dulaglutide.

问 AI

Bookmark

View Full Paper